DOCSLIB.ORG

Gao Potentiates Estrogen Receptor a Activity Via the ERK Signaling Pathway

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gao Potentiates Estrogen Receptor a Activity Via the ERK Signaling Pathway 45 Gao potentiates estrogen receptor a activity via the ERK signaling pathway Melyssa R Bratton1,2, James W Antoon1, Bich N Duong1, Daniel E Frigo5, Syreeta Tilghman1,2, Bridgette M Collins-Burow1, Steven Elliott1, Yan Tang2, Lilia I Melnik2, Ling Lai3, Jawed Alam4, Barbara S Beckman2, Steven M Hill3, Brian G Rowan1, John A McLachlan2 and Matthew E Burow1 1Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, 1430 Tulane Avenue, SL-78, New Orleans, Louisiana 70112, USA Departments of 2Pharmacology and 3Structural and Cellular Biology, Tulane University, New Orleans, Louisiana 70112, USA 4Department of Medical Genetics, Alton-Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA 5Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, Texas 77204, USA (Correspondence should be addressed to M E Burow; Email: [email protected]) Abstract The estrogen receptor a (ERa) is a transcription factor that cancer cell line MCF-7 showed that Gao augments the mediates the biological effects of 17b-estradiol (E2). ERa transcription of several ERa-regulated genes. Western blots of transcriptional activity is also regulated by cytoplasmic HEK293T cells transfected with ERGGao revealed that Gao signaling cascades. Here, several Ga protein subunits were stimulated phosphorylation of ERK 1/2 and subsequently tested for their ability to regulate ERa activity. Reporter increased the phosphorylation of ERa on serine 118. In assays revealed that overexpression of a constitutively active summary, our results show that Gao, through activation of the Gao protein subunit potentiated ERa activity in the absence MAPK pathway, plays a role in the regulation of ERa activity. and presence of E2. Transient transfection of the human breast Journal of Endocrinology (2012) 214, 45–54 Introduction Activation of the ERa by cytoplasmic signaling cascades is not limited to PGFs. Recent evidence suggests that factors Various agents regulate estrogen receptor a (ERa) activity in that activate G-protein-coupled receptors (GPCRs) may also addition to 17b-estradiol (E2), including peptide growth regulate ERa function. Dopamine has been shown to activate factors (PGFs) such as epidermal growth factor (EGF) and ER-mediated transcriptional activity in the absence (Power insulin-like growth factor 1 (IGF1; Ignar-Trowbridge et al. et al. 1991) or presence (Smith et al. 1993)ofE2. Melatonin 1992, 1993, 1996, Aronica & Katzenellenbogen 1993, Curtis has been shown to inhibit breast cancer cell proliferation et al. 1996, Kenney & Dickson 1996, Lee et al. 2001, Klotz through modulation of ERa function (Ram et al. 1998, et al. 2002). PGFs and E2 often operate in concert to 2000b, Rato et al. 1999, Yuan et al. 2002, Girgert et al. 2003, potentiate/elevate ERa activity to a level above that observed del Rio et al. 2004). Indeed, melatonin may play a role in with either factor alone (Ignar-Trowbridge et al. 1993, 1996). breast cancer (Sanchez-Barcelo et al.2003), as high Mechanistic studies have revealed that cross talk between the concentrations of melatonin in human breast cancer tissue PGF and E2 signaling cascades occurs at the level of ERa,in have been correlated with good prognosis (Maestroni 1999). that PGF activation of cytoplasmic signaling cascades such as Also, the growth and proliferation of a number of breast the phosphatidylinositol 3-kinase (PI3K)–AKT and MAPK cancers are influenced by b-adrenergic receptors (Cakir et al. signaling cascades (Dufourny et al. 1997, Bartucci et al. 2001, 2002), and b-adrenergic stimulation has been shown to elicit Dunn et al. 2001, Kato 2001, Brazil et al. 2002, Cantley 2002) classical ‘estrogenic’ responses, such as increases in uterine ultimately leads to activation of ERa (Martin et al. 2000, weight and ER levels (Re et al. 1993, Sukocheva et al. 2003). Campbell et al. 2001). The MAPKs, including ERK1/2, Specificity of GPCR signaling is determined by the types c-jun N-terminal kinase (JNK), and p38 kinase, are a family of of heterotrimeric GTP-binding proteins (G-proteins) that are related kinases stimulated by numerous extracellular stimuli recruited to, and activated by, an individual receptor including mitogens, peptide hormones, cytokines, and (Rockman et al. 2002). The G-proteins consist of a-, b-, cellular stress (Ballif & Blenis 2001). and g-subunits, and they function as second messengers that Journal of Endocrinology (2012) 214, 45–54 DOI: 10.1530/JOE-12-0097 0022–0795/12/0214–045 q 2012 Society for Endocrinology Printed in Great Britain Online version via http://www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/30/2021 05:40:19PM via free access 46 M R BRATTON and others . Gao promotes ERa via Erk signaling initiate signaling cascades responsible for the regulation of and BCL2. Mechanistic studies on Gao revealed that this numerous cellular events. The Ga subunit family includes subunit activated the ERK1/2 signaling pathway, culminating four distinct subgroups, Gas,Gai/o,Gaq, and Ga12 (Downes in the phosphorylation of ERa. & Gautam 1999, Radhika & Dhanasekaran 2001), and There is emerging evidence linking the ER to nonclassical, mutations in Ga subgroups have been linked to human rapid signaling events originating at the cell membrane diseases (Lania et al. 2001, Schulte & Fredholm 2003). followed by activation of downstream kinase cascades within Classically, Gai inhibits and Gas stimulates cAMP production. the cytoplasm. This study focuses on the ability of the However, Ga signaling is not limited to the cAMP pathway, G-protein Gao to modulate the activity of the ER and as all four Ga subgroups have been shown to regulate kinase- explores the cellular pathways through which this regulation mediated signaling events, including the MAPK and PI3K– takes place. AKT pathways (Nava et al. 2002, Marinissen et al. 2003, Radeff-Huang et al. 2004). For example, sphingosine kinase type 1 (SPHK1), the enzyme that phosphorylates sphingosine Materials and Methods to form sphingosine 1 phosphate, has been shown to regulate breast cancer cell proliferation and tumorigenesis, Reagents possibly through SPHK1’s ability to regulate the level of phosphorylated AKT and ERK1/2 (Nava et al.2002, DMEM, phenol red-free DMEM, fetal bovine serum (FBS), Sukocheva et al. 2003). BME amino acids, MEM amino acids, L-glutamine, Recent studies have demonstrated pathological Ga penicillin, streptomycin, and sodium pyruvate were obtained signaling in several disease types, including immune system from GibcoBRL. Porcine insulin was purchased from Sigma, dysfunction, infectious diseases, endocrine disorders, heart and charcoal-stripped (CS) FBS was obtained from HyClone disease, and cancer (Kimple et al. 2011, Vassart & Costagliola (Logan, UT, USA). Effectene was purchased from Qiagen. 2011, Kaur et al. 2012). In the endocrine system, altered Ga E2 was obtained from Sigma. BrightGlo luciferase assay has been found in a number of disorders, including those substrate was purchased from Promega. The lysis buffer used involving the thyroid, hypothalamus, pituitary, pancreas, was mammalian protein extraction reagent (M-PER) from ovaries, prostate, and breast (Livingstone et al. 1998, Lania Pierce (Rockford, IL, USA). The Berthold AutoLumat Plus et al. 2001, D’Souza et al. 2004, Cotta-Grand et al. 2009, luminometer was used for luciferase assays. Ogawa et al. 2009, Zhao et al. 2010). In cancer, aberrant Gao signaling has been found in teratocarcinoma, glioblastoma, Plasmids neuroblastoma, colon, kidney, lung, gastrointestinal stromal- tumors, acute myeloid leukemia, ovarian, pancreas, thyroid, Expression constructs for constitutively active Ga subunits and breast cancers (Hurst & Hooks 2009, Lamba et al. 2009, (GTPase-deficient mutants of Gao,Gai2,Gaq,Ga12,Ga13, Kimple et al. 2011). Recent findings have shed light on the and Ga16) were generously provided by Dr Lynn Heasley role of Gao signaling in breast carcinoma. Several somatic (Heasley et al. 1996) or obtained through the UMR cDNA mutations in Gao have been identified and characterized in Resource Center (Rolla, MO, USA). We have previously patient breast biopsies (Ram et al. 2000a, Lamba et al. 2009, described the use of dominant-negative mutant ERK2-DN, Kan et al. 2010, Garcia-Marcos et al. 2011). These mutations which was provided by Drs Melanie Cobb and Roger Davis primarily result in a constitutively active Gao phenotype in (Frigo et al. 2004). The pcDNA3.1-ERa plasmids along with breast tumors, leading to increased Gao signaling. However, pERE-Luc plasmid, which contains three copies of the the exact mechanism and consequence of enhanced Gao estrogen response element (ERE) linked to the luciferase signaling in breast cancer remains poorly characterized. A gene, were purchased from Panomics (Fremont, CA, USA). better understanding of the role of Gao in ERa signaling ERa-S118A was provided by Benita Katzenellenbogen would increase our understanding of the mechanisms of (Le Goff et al. 1994). cancer biology. Given the ability of GPCRs to activate cytoplasmic signaling events that have previously been shown Cell culture to potentiate ERa transcriptional activity, we hypothesized that G-protein-coupled signaling pathways may target and The two cell lines used were the ER-negative human regulate the transcriptional activity of ERa. The recent embryonic kidney 293 (HEK293; Le Goff et al. 1994), and the identification of naturally occurring Gao mutants led us to use ERa- and ERb-positive human breast carcinoma (MCF-7) a constitutively active Gao vector to simulate the effects of the cell lines (Frigo et al. 2002). All were maintained in DMEM mutations found in clinical breast tumors. Given the relatively supplemented with 10% FBS, BME amino acids, MEM novel discovery of these mutations, in vitro and in vivo models amino acids, L-glutamine, 100 units/ml penicillin, of specific Gao clinical mutations are currently unavailable. 100 units/ml streptomycin, sodium pyruvate, and 1! K10 We demonstrated potentiation of ERa activity by Gao, which 10 M porcine insulin under mycoplasma-free conditions culminated in increased expression of the estrogen target at 37 8C in humidified 5% CO2.
Load more

Recommended publications
  • Diverse Signaling Pathways Modulate Nuclear Receptor Recruitment of N-Cor and SMRT Complexes (Estrogen Receptor͞tamoxifen͞corepressor Complex)
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 2920–2925, March 1998 Biochemistry Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes (estrogen receptorytamoxifenycorepressor complex) ROBERT M. LAVINSKY*†,KRISTEN JEPSEN*†,THORSTEN HEINZEL*, JOSEPH TORCHIA*, TINA-MARIE MULLEN‡, RACHEL SCHIFF§,ALFONSO LEON DEL-RIO*, MERCEDES RICOTE¶,SALLY NGO¶,JOSLIN GEMSCH‡, SUSAN G. HILSENBECK§,C.KENT OSBORNE§,CHRISTOPHER K. GLASS¶,MICHAEL G. ROSENFELD*, \ AND DAVID W. ROSE‡ *Howard Hughes Medical Institute, ¶Cellular and Molecular Medicine, ‡Whittier Diabetes Program, and †UCSD Graduate Program in Biology, Department and School of Medicine, University of California at San Diego, La Jolla, CA 92093-0648; and §Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284-7884 Contributed by Michael G. Rosenfeld, January 9, 1998 ABSTRACT Several lines of evidence indicate that the partial agonistic activity (31). Various agents that raise intra- nuclear receptor corepressor (N-CoR) complex imposes li- cellular cAMP levels or stimulate the rasyMAP kinase path- gand dependence on transcriptional activation by the retinoic way can similarly cause estrogen receptor (ER) activation in acid receptor and mediates the inhibitory effects of estrogen the presence of tamoxifen or the absence of any activating receptor antagonists, such as tamoxifen, suppressing a con- ligand (9, 32–35). In this manuscript we show that diverse stitutive N-terminal, Creb-binding proteinycoactivator com- molecular strategies regulate the association of N-CoR- or plex-dependent activation domain. Functional interactions SMRT-containing complexes with specific nuclear receptors, between specific receptors and N-CoR or SMRT corepressor including the nature of the ligand, the levels of available complexes are regulated, positively or negatively, by diverse N-CoRySMRT, and the action of diverse protein kinase- signal transduction pathways.
    [Show full text]
  • STEROID RECEPTORS in HEALTH and DISEASE SERONO SYMPOSIA, USA Series Editor: James Posillico
    STEROID RECEPTORS IN HEALTH AND DISEASE SERONO SYMPOSIA, USA Series Editor: James Posillico ACROMEGALY: A Century of Scientific and Clinical Progress Edited by Richard J. Robbins and Shlomo Melmed BASIC AND CLINICAL ASPECTS OF GROWTH HORMONE Edited by Barry B. Bercu THE PRIMATE OVARY Edited by Richard L. Stouffer SOMATOSTATIN: Basic and Clinical Status Edited by Seymour Reichlin STEROID RECEPTORS IN HEALTH AND DISEASE Edited by Virinder K. Moudgil A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further infor­ mation please contact the publisher. STEROID RECEPTORS IN HEALTH AND DISEASE Edited by Virinder K. Moudgil Oakland University Rochester, Michigan PLENUM PRESS • NEW YORK AND LONDON library of Congress Cataloging in Publication Data Meadow Brook Conference on Steroid Receptors in Health and Disease (tst(tst:: t987 : Rochester, Mich .) Ste roid receptors in health and disease / edited by Virinder K. Moudgil. p. cm . "Proc" Proceedingseedings of the Meadow Brook Conference on Steroid Receptors in Health and Disease, spon­ sored by Serono Symposia. USA and Oakland University. held September 20-23, 19871987.. in Rochester. Michigan ··-T.p. verso. Includes bibliographies and indexes. IS8N 978-1-4684-5543-4 IS8N 978-1-4684-5541-0 (eBook) 00110.1007/978-1-4684-5541-0 I . Steroid hormones-Receptors-Congresses. 1. Moudgil, V.V. K.K. (Virinder K.), 1945- . 11. Sereno Symposia, USA. III.Ill. Oakland Universityly. IV. Title. [oNlM[oNlM:: tt. Receptors , Sleroid-congresses. W3 ME3781st 1987s / WK 150 M482 1987sJ1987sj oP571.7.M42 1987 512 '.
    [Show full text]
  • Workshop 1.4 Nature of the Ligand-Binding Pocket
    Pure Appl. Chem., Vol. 75, Nos. 11–12, pp. 2397–2403, 2003. © 2003 IUPAC Workshop 1.4 Nature of the ligand-binding pocket of estrogen receptor a and b: The search for subtype- selective ligands and implications for the prediction of estrogenic activity* John A. Katzenellenbogen‡, Rajeev Muthyala, and Benita S. Katzenellenbogen Departments of Chemistry, Molecular and Integrative Physiology, University of Illinois, Urbana, 61801 IL, USA Abstract: The ligand-binding pockets of estrogen receptor alpha and beta (ERα and ERβ) ap- pear to have subpockets of different size and flexibility. To find ligands that will discriminate between the two ER subtypes on the basis of affinity or efficacy, we have prepared com- pounds of varying size, shape, and structure. We have evaluated the binding affinity of these compounds and their potency and efficacy as transcriptional activators through ERα and ERβ. In this manner, we have identified a number of ligands that show pronounced ER sub- type selectivity. These studies also highlight the eclectic structure–activity relationships of estrogens and the challenges inherent in developing computational methods for the predic- tion of estrogenic activity. INTRODUCTION The actions of estrogens are mediated by the estrogen receptor (ER), an intracellular protein that func- tions as a ligand-regulated transcription factor [1]. There are two subtypes of the estrogen receptor, ER α and ERβ; these subtypes have different tissue distributions and are thought to regulate different estro- gen responses [2]. Therefore, ligands that are selective in activating or inhibiting these two subtypes could have a desirable pattern of pharmacological activity that might be useful in regulating fertility, in treating menopausal symptoms, and in preventing and treating breast cancer [1].
    [Show full text]
  • A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: the Origins of Targeted Therapy and Chemoprevention
    Published OnlineFirst February 10, 2009; DOI: 10.1158/0008-5472.CAN-09-0029 AACR Centennial Series A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention V. Craig Jordan Fox Chase Cancer Center, Philadelphia, Pennsylvania Abstract all the available clinical cases of oophorectomy to treat breast The origins of the story to decipher the mechanisms that cancer in Great Britain in perhaps the first ‘‘clinical trial.’’ Boyd control the growth of sex hormone–dependent cancers started concluded that only one-third of metastatic breast tumors more than 100 years ago. Clinical observations of the responded to oophorectomy. This clinical result and overall apparently random responsiveness of breast cancer to response rate has remained the same to this day. endocrine ablation (hormonal withdrawal) provoked scientif- Unfortunately, responses were of limited duration and enthusi- ic inquiries in the laboratory that resulted in the development asm waned that this approach was the answer to cancer treatment. of effective strategies for targeting therapy to the estrogen The approach of endocrine ablation was only relevant to breast receptor (ER; or androgen receptor in the case of prostate cancer (and subsequently prostate cancer; ref. 4), thus, the cancer), the development of antihormonal treatments that approach was only effective in a small subset of all cancer types. At the dawn of the 20th Century, there was no understanding of the dramatically enhanced patient survival, and the first success- ful testing of agents to reduce the risk of developing any endocrine system or hormones. Nevertheless, laboratory studies cancer.
    [Show full text]
  • New Compounds Block Master Regulator of Cancer Growth, Metastasis 7 January 2020, by Diana Yates
    New compounds block master regulator of cancer growth, metastasis 7 January 2020, by Diana Yates The researchers focused on FOXM1 because it is found in higher abundance in cancer cells than in healthy human cells, said Benita Katzenellenbogen, a University of Illinois professor of molecular and integrative physiology who led the study with U. of I. chemistry professor John Katzenellenbogen and life sciences research specialist Yvonne Ziegler. "FOXM1 is a key factor that makes breast cancer and many other cancers more aggressive and more difficult to treat," Benita Katzenellenbogen said. "Because it is a master regulator of cancer growth and metastasis, there has been great interest in developing compounds that would be effective in blocking it." Researchers including, from left, graduate student Valeria Sanabria Guillen, research scientist Sung Hoon So far, no successful drug agents have been Kim, researcher Kathy Carlson, chemistry professor developed to reduce the effects of FOXM1, John John Katzenellenbogen, research specialist Yvonne Katzenellenbogen said. Ziegler, and molecular and integrative physiology professor Benita Katzenellenbogen developed new drug "There are reports of other inhibitors of FOXM1, but agents to inhibit a pathway that contributes to cancer. these are generally less potent and do not work The compounds killed cancer cells and reduced the growth of breast cancer tumors in mice. Credit: L. Brian well in the body," he said. "Our compounds have Stauffer good anti-tumor activity in animal models. They behave well in vivo and have long half-lives in the blood. Some work well when given orally, which is desirable for ultimate patient use." Scientists have developed new drug compounds that thwart the pro-cancer activity of FOXM1, a The researchers developed the new drugs by transcription factor that regulates the activity of analyzing the properties of various compounds in a dozens of genes.
    [Show full text]
  • Positive Cross-Talk Between Estrogen Receptor and NF-Κb in Breast Cancer
    Published OnlineFirst November 17, 2009; DOI: 10.1158/0008-5472.CAN-09-2608 Endocrinology Positive Cross-Talk between Estrogen Receptor and NF-κB in Breast Cancer Jonna Frasor,1 Aisha Weaver,1 Madhumita Pradhan,1 Yang Dai,2 Lance D. Miller,3 Chin-Yo Lin,4 and Adina Stanculescu1 Departments of 1Physiology and Biophysics and 2Bioengineering, University of Illinois at Chicago, Chicago, Illinois; 3Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; and 4Department of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah Abstract aggressive with earlier metastatic recurrence (1–3). Gene expres- Estrogen receptors (ER) and nuclear factor-κB(NF-κB) are sion profiling has further delineated the two types of ER-positive known to play important roles in breast cancer, but these fac- tumors, referred to as intrinsic subtypes luminal A and luminal B, tors are generally thought to repress each other's activity. with the luminal A subtype associated with good patient outcome However, we have recently found that ER and NF-κB can also and the B subtype with a poor survival rate (4, 5). Interestingly, activation of the proinflammatory transcription factor nuclear act together in a positive manner to synergistically increase κ κ gene transcription. To examine the extent of cross-talk be- factor- B(NF-B) may play a role in this dichotomy between ER-positive tumors. Constitutive activation of NF-κBinbreast tween ER and NF-κB, a microarray study was conducted in tumors is associated with more aggressive ER-positive tumors which MCF-7 breast cancer cells were treated with 17β- (6, 7), the development of resistance to endocrine therapy (8, 9), estradiol (E ), tumor necrosis factor α (TNFα), or both.
    [Show full text]
  • In This Issue Winter 2019 Newsletter Greetings From
    GREETINGS FROM THE HEAD WINTER 2019 NEWSLETTER Claudio Grosman IN THIS ISSUE Welcome everyone to the 2019 edition of the Greetings from the head 1 MIP Newsletter! I hope that this year has been healthy, and productive for everyone, and that 2020 bodes even Professor Lori Raetzman: From Backyard better for realizing our dreams—scientific or otherwise. Biology to Pituitary Proficiency 1-3 Yes, time flies; one more year has gone by. Professor Dan Llano: From Swinging Bats to If I had to identify one of the happiest moment for Echolocating Bats 3-4 me, in 2019, in my role as Department Head, I would Alumni Highlights - Dr. Janelle Mapes 4 definitely choose the promotion of our colleague Sayee Anakk to Associate Professor with indefinite tenure. Alumni Highlights - Dr. Kirsten Eckstrum 5 Congratulations Sayee! It gives me immense joy to see Alumni Highlights - Dr. Congcong Chen 5 young faculty succeeding not only scientifically but also in teaching and service to the Department. I find that despite being a small Department, the faculty of New MIP Graduate Students 5 MIP step up to a number of administrative tasks and devote time outside of the MIP Retreat and Halloween Party 5 labs or the classroom. I am very grateful for that. Student and Postodc Award/Grant 6 This issue of the MIP Newsletter has been revamped to feature interviews of MIP faculty --Assoc. Prof. Lori Raetzman and Assoc. Prof. Dan Llano PHD Awarded 6 conducted by graduate students Adam Nelson (Nelson lab) and James Nguyen Alumni Updates 6 (Anakk lab), respectively. It also features updates from three of our student alumni Dr.
    [Show full text]
  • Curriculum Vitae - Rex A
    CURRICULUM VITAE - REX A. HESS Date of Preparation: July 2008 TABLE OF CONTENTS 1.0 PERSONAL HISTORY AND PROFESSIONAL EXPERIENCE 1.1 Mailing Address: ←Dr. Rex A. Hess ←Department of Veterinary Biosciences University of Illinois 2001 S. Lincoln Urbana, IL 61802- 6199 Phone: 217-333-8933 / 333-1696 (lab) Fax: 217-244-1652 Email: [email protected] HomePage: http://www.cvm.uiuc.edu/~rexhess 1.2 Citizenship: United States of America 1.3 Educational History: ←B.S. Education/Zoology cum laude, University of Missouri-Columbia 1971 ←M.S.Physiology Area, University of Missouri-Columbia 1975 ←Ph.D. Animal Physiology, Clemson University 1983 1.4 List of Academic Positions since Final Degree 1983-1986 Postdoc; Health Effects Res. Lab, U.S. Environmental Protection Agency, RTP, N.C 1986-1992 Assistant Professor, University of Illinois-Urbana, Champaign; Faculty Director of Microscopic Imaging Laboratory 1992-1993 Interim Director; Center for Electron Microscopy, University of Illinois 1992-1995 Adjunct Scientist; Yerkes Regional Primate Research Center, Emory University Affiliate; Institute for Environmental Studies, University of Illinois 1992-1998 Associate Professor; Dept. of Veterinary Biosciences, University of Illinois 1995-2003 Director of Center for Microscopic Imaging, University of Illinois 1998- Professor; Department of Veterinary Biosciences, University of Illinois Chair of Morphology Division, Department of Veterinary Biosciences 1998-2002 Director and PI, NIEHS Training Grant in Environmental Toxicology 2002- Associate Director, NIEHS Training Grant in Environmental Toxicology 2005- Affiliate member, Institute for Genomic Biology, University of Illinois 1.5 Other Professional Employment ←1973-1976 Electron Microscopy; Veterans Administration Hospital, Columbia, MO ←1976-1979 Research Associate; Washington University School of Medicine, St.
    [Show full text]
  • Molecular Determinants of Tissue Selectivity in Estrogen Receptor Modulators
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14105–14110, December 1997 Pharmacology Molecular determinants of tissue selectivity in estrogen receptor modulators TIMOTHY A. GRESE*, JAMES P. SLUKA*, HENRY U. BRYANT,GEORGE J. CULLINAN,ANDREW L. GLASEBROOK, CHARLES D. JONES,KEN MATSUMOTO,ALAN D. PALKOWITZ,MASAHIKO SATO,JOHN D. TERMINE, MARK A. WINTER,NA N. YANG, AND JEFFREY A. DODGE* Endocrine Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 Edited by Paul Talalay, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved October 3, 1997 (received for review July 3, 1997) ABSTRACT Interaction of the estrogen receptoryligand molecular conformation of individual ligands (11–14). The complex with a DNA estrogen response element is known to recent characterization of a new ER isoform, ERb, adds a regulate gene transcription. In turn, specific conformations of further layer of complexity, because ligands with different the receptor-ligand complex have been postulated to influence structural characteristics may exhibit different binding profiles unique subsets of estrogen-responsive genes resulting in differ- depending on which ER isoform is being evaluated (15, 16). ential modulation and, ultimately, tissue-selective outcomes. The To date, ER ligands have been grouped into four classes on the estrogen receptor ligands raloxifene and tamoxifen have dem- basis of in vivo pharmacology, and representatives of these classes onstrated such tissue-specific estrogen agonistyantagonist ef- indeed have been shown to exhibit unique profiles with respect to fects. Both agents antagonize the effects of estrogen on mammary transcriptional activation (9). Differential effects on mammary, tissue while mimicking the actions of estrogen on bone.
    [Show full text]
  • CHERIAN-DISSERTATION-2018.Pdf
    NOVEL TOOLS TO IDENTIFY ESTROGEN REGULATED GENES IMPORTANT FOR BREAST AND OVARIAN CANCER CELL PROLIFERATION BY MATHEW MUTHUTHOTTATHU CHERIAN DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Molecular and Integrative Physiology in the Graduate College of the University of Illinois at Urbana-Champaign, 2018 Urbana, Illinois Doctoral Committee: Professor David Shapiro, Chair Professor Jongsook Kim Kemper Associate Professor Lori Raetzman Assistant Professor Eric C. Bolton Abstract Estrogens are steroid hormones produced by the ovaries and extra ovarian tissues including the adrenal gland and adipose tissue. There are 3 major physiologically relevant estrogens in the human body, the most potent and biologically relevant of which is 17b-estradiol (E2). E2 exerts its physiologic functions by acting through two isoforms of Estrogen Receptor (ER); ERa and ERb. ERs are normally bound to heat shock chaperone proteins but once E2 diffuses across the cell membrane and binds to the ligand binding pocket of ER it sheds these proteins, homodimerizes and binds to DNA recruiting transcriptional machinery and upregulating a number of target genes including those important for proliferation. Estrogens acting through ERa play a central role in the proliferation of breast and ovarian cancer cells as evidenced by the mainstay clinical adjuvant therapies for breast cancer which target the ligand pocket of estrogen receptor by either competitively displacing endogenous ligand, or by inhibiting the rate dependent enzymes responsible for synthesizing the endogenous ligand. While the importance of E2-ERa as a central regulator in breast cancer proliferation is unquestioned, it remains unclear how ERa is activated when the clear majority of women who develop breast cancer are post-menopausal.
    [Show full text]
  • Acetylation of Estrogen Receptor by P300 at Lysines 266 and 268
    0888-8809/06/$15.00/0 Molecular Endocrinology 20(7):1479–1493 Printed in U.S.A. Copyright © 2006 by The Endocrine Society doi: 10.1210/me.2005-0531 Acetylation of Estrogen Receptor ␣ by p300 at Lysines 266 and 268 Enhances the Deoxyribonucleic Acid Binding and Transactivation Activities of the Receptor Mi Young Kim, Eileen M. Woo, Yee Ting Esther Chong, Daria R. Homenko, and W. Lee Kraus Department of Molecular Biology and Genetics (M.Y.K., Y.T.E.C., D.R.H., W.L.K.), Cornell University, Ithaca, New York 14853; Laboratory of Chromatin Biology and Epigenetics (E.M.W.), The Rockefeller University, and Department of Pharmacology (W.L.K.), Weill Medical College of Cornell University, New York, New York 10021 Using a variety of biochemical and cell-based ap- tive enzymes (i.e. class III deacetylases, such as proaches, we show that estrogen receptor ␣ (ER␣) sirtuin 1). Acetylation at Lys266 and Lys268, or sub- is acetylated by the p300 acetylase in a ligand- and stitution of the same residues with glutamine (i.e. steroid receptor coactivator-dependent manner. K266/268Q), a residue that mimics acetylated ly- Using mutagenesis and mass spectrometry, we sine, enhances the DNA binding activity of ER␣ in identified two conserved lysine residues in ER␣ EMSAs. Likewise, substitution of Lys266 and (Lys266 and Lys268) that are the primary targets of Lys268 with glutamine enhances the ligand-depen- p300-mediated acetylation. These residues are dent activity of ER␣ in a cell-based reporter gene acetylated in cells, as determined by immunopre- assay. Collectively, our results implicate acetyla- cipitation-Western blotting experiments using an tion as a modulator of the ligand-dependent gene antibody that specifically recognizes ER␣ acety- regulatory activity of ER␣.
    [Show full text]
  • Mutation of the Palmitoylation Site of Estrogen Receptor Α in Vivo Reveals
    Mutation of the palmitoylation site of estrogen PNAS PLUS receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions Marine Adlanmerinia, Romain Solinhaca,1, Anne Abota,1, Aurélie Fabrea,1, Isabelle Raymond-Letronb, Anne-Laure Guihotc, Frédéric Boudoua, Lucile Sautiera,b, Emilie Vessièresc, Sung Hoon Kimd, Philippe Lièree, Coralie Fontainea, Andrée Krustf, Pierre Chambonf,2, John A. Katzenellenbogend, Pierre Gourdya, Philip W. Shaulg, Daniel Henrionc, Jean-François Arnala,2, and Françoise Lenfanta aInstitut National de la Santé et de la Recherche Médicale U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, 31 432 Toulouse Cedex 4, France; bInstitut National Polytechnique, École Nationale Vétérinaire de Toulouse, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Service 006, Université de Toulouse, F-31076 Toulouse, France; cInstitut National de la Santé et de la Recherche Médicale U1083, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6214, Université d’Angers, 49000 Angers, France; dDepartment of Chemistry, University of Illinois at Urbana–Champaign, Urbana, IL 61820; eInstitut National de la Santé et de la Recherche Médicale, Université Paris Sud, 94270 Kremlin Bicêtre, France; fInstitut de Génétique et de Biologie Moléculaire et Cellulaire, Collège de France, Université de Strasbourg, FR-67404 Illkirch, France; and gDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75235 Contributed by Pierre Chambon, November 27, 2013 (sent for review October 7, 2013) Estrogen receptor alpha (ERα) activation functions AF-1 and AF-2 to minutes), nonnuclear signal transduction, usually termed classically mediate gene transcription in response to estradiol (E2).
    [Show full text]